Glucotrack, Inc. Announces Reverse Stock Split

Business Wire

Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today announced that it will effect a 1-for-2 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock, par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, October 26, 2026.

Glucotrack’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK.” The new CUSIP number for the Common Stock following the Reverse Stock Split will be 45824Q879.

The material effects of the Reverse Stock Split will be:

Every two (2) shares of Glucotrack’s issued and outstanding Common Stock will be combined into one (1) share of Common Stock.

The number of total outstanding shares of Common Stock will be proportionally reduced from 2,368,237 shares to approximately 1,184,119 shares.

The ownership percentage of each Glucotrack stockholder will remain unchanged, other than as a result of fractional shares. No fractional shares of Common Stock will be issued in connection with the Reverse Stock Split. Instead, stockholders who otherwise would be entitled to receive fractional shares because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will automatically be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.

At the annual meeting of stockholders held on August 18, 2026, the stockholders of the Company approved a proposal to authorize the Company’s management to file one or more certificates of amendment to the Company’s certificate of incorporation to effect one or more reverse stock splits at an aggregate ratio not to exceed 1-for-30, as determined by the Company’s management in its sole discretion. On August 28, 2026, the Company implemented a 1-for-15 reverse stock split.

Among other considerations, the Reverse Stock Split is intended to help Glucotrack regain compliance with the $1.00 minimum bid price requirement for continued listing of its Common Stock on Nasdaq under Nasdaq Listing Rule 5550(a)(2) and to make the prevailing price of its Common Stock more attractive to a broader group of institutional investors. Under the terms of the exception granted to the Company by the Nasdaq Hearings Panel (the “Panel”), the Company must maintain a closing bid price of at least $1.00 for each trading day until November 9, 2026. In addition, if the Company becomes non-compliant with any other Nasdaq Listing Rule during the term of the exception, it will have seven (7) calendar days to advise the Panel of its plan to cure the deficiency, and the Panel will then determine whether to grant the Company an exception to cure the deficiency or to delist the Company. The Panel has also reserved the right to reconsider the terms of the exception based on any event, condition or circumstance that, in the opinion of the Panel, would make continued listing of the Company’s securities on Nasdaq inadvisable or unwarranted. Accordingly, if the Company fails to satisfy the terms of the exception, or if the Panel reconsiders those terms, the Company’s securities may be delisted from Nasdaq.

The combination of, and reduction in, the number of issued and outstanding shares of Common Stock as a result of the Reverse Stock Split will occur automatically at the opening of trading on October 26, 2026, without any additional action on the part of Glucotrack’s stockholders. Glucotrack’s transfer agent, VStock Transfer, LLC, is acting as the exchange agent for the Reverse Stock Split and will send each stockholder a transaction statement indicating the number of shares of Common Stock the stockholder holds after the Reverse Stock Split. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such nominee’s particular processes. Such stockholders will not be required to take any action in connection with the Reverse Stock Split.

Additional information regarding the Reverse Stock Split can be found in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on July 17, 2026. A link to this document is available at https://www.sec.gov.

About Glucotrack, Inc.

Glucotrack, Inc. (Nasdaq: GCTK) operates Lōkahi Therapeutics™, a biopharmaceutical platform focused on advancing innovative therapeutic opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through its ai² platform, Lōkahi Therapeutics™ seeks to identify, evaluate, and advance differentiated healthcare and life sciences opportunities. For more information, please visit www.lokahithera.com. In addition, through its subsidiary Glucotrack Technologies, Inc., the Company is focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an investigational device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate,” “believe,” “expect,” “intend,” “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on Glucotrack or its business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. These factors include, but are not limited to: the anticipated benefits of the Reverse Stock Split, including the effect the Reverse Stock Split will have on the Company’s ability to maintain compliance with the Nasdaq listing standards; the effect of the Reverse Stock Split on the market price and liquidity of the Common Stock; the Company’s ability to maintain a closing bid price of at least $1.00 for each trading day until November 9, 2026; the Company’s ability to comply with the terms of the exception granted by the Panel and with other Nasdaq listing requirements, and the Panel’s discretion to grant or deny any further exception or to reconsider the terms of the exception; the risk that the Company’s securities may be delisted from Nasdaq if it fails to maintain compliance with applicable listing requirements; the ability to make the Company’s Common Stock more attractive to institutional investors; the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.